<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577638</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1-39-007</org_study_id>
    <nct_id>NCT04577638</nct_id>
  </id_info>
  <brief_title>Accelerated Radio-Immunotherapy for Lung Cancer</brief_title>
  <acronym>AIRING</acronym>
  <official_title>A Phase II Trial Evaluating Conformational Intensity Modulated Radiotherapy With Concomitant Nivolumab Followed by Nivolumab for Patients With Locally Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy (RT), at a total dose of 60-66 Gy over 6 weeks, combined with platinum-based&#xD;
      chemotherapy, is the standard of care for stage III Non-Small Cell Lung Cancers (NSCLC)&#xD;
      patients with unresectable or inoperable disease. However, the long-term outcomes are poor,&#xD;
      with a 5-year overall survival (OS) rate of 15-35% for stage IIIA, and 5-10% for stage IIIB&#xD;
      patients. The recent association of immunotherapy has been proven to improve Progression Free&#xD;
      Survival (PFS) and OS for these patients and durvalumab consolidation following&#xD;
      chemoradiotherapy (CT-RT) is now the new standard of care.&#xD;
&#xD;
      Compared to older technics (2Dimensions(D) and 3D-RT), intensity-modulated radiotherapy&#xD;
      (IMRT) allows for improved organs-at-risk sparing, owing to the high dose conformation to the&#xD;
      target volume, thus reducing toxicity rates.&#xD;
&#xD;
      In regard to the recent results of adjuvant immunotherapy, the benefits of concomitant&#xD;
      chemotherapy with radiotherapy could be re-evaluated. With the changing landscape in the&#xD;
      standard treatment of Local Advanced NSCLC (LA-NSCLC), the reduction in treatment-induced&#xD;
      toxicity, while maintaining optimal tumor control, has become a priority, thereby warranting&#xD;
      access to adjuvant immunotherapy for these patients. Due to the toxicity of the&#xD;
      chemoradiotherapy, a large subset of patients may be unfit for the adjuvant immunotherapy.&#xD;
      The use of immunotherapy concomitant to radiotherapy without chemotherapy may be the next&#xD;
      step. Nevertheless, as immune cells are highly sensitive to conventional RT doses, the&#xD;
      paradigm of the standard irradiation volumes should be reconsidered. In this context, the&#xD;
      introduction of IMRT to spare lymphatic tissues and bone marrow deserves evaluation in&#xD;
      prospective trials.&#xD;
&#xD;
      A strong body of evidence supports the combination of RT with immunotherapy such as a&#xD;
      Programmed cells Death-1 (PD1) inhibitor. Radiation alone can modify the immune response in&#xD;
      several ways to allow for synergistic effects when combined with immunotherapy.&#xD;
&#xD;
      The reduction in treatment-induced toxicity while maintaining optimal tumor control has&#xD;
      become a priority, thereby warranting access to adjuvant immunotherapy for these patients. In&#xD;
      this context, the introduction of IMRT to spare lymphatic tissues and bone marrow deserves&#xD;
      evaluation in prospective trials.&#xD;
&#xD;
      The timing of administration of immunotherapy seems to be a major point. Previous data in&#xD;
      mice showed that an improved survival benefit with concurrent anti-PD-Ligand1 (PD-L1) and RT&#xD;
      versus sequential administration. Moreover, for sequential schedule, an improved survival&#xD;
      outcome was found for patients receiving first dose of durvalumab within 14 days of last&#xD;
      radiotherapy fraction compared to 14 days or greater.&#xD;
&#xD;
      Furthermore, immunotherapy combined with radiotherapy appears to be safe, without increase of&#xD;
      the toxicity.&#xD;
&#xD;
      In summary, there is a strong rationale for testing this new paradigm of accelerated IMRT&#xD;
      combined with concurrent and maintenance nivolumab for locally advanced non-small lung&#xD;
      cancer, due to:&#xD;
&#xD;
        -  The unmet medical need for new Standard Of Care (SOC) better tolerated and &quot; as &quot; or &quot;&#xD;
           more &quot; effective treatment than CT-RT&#xD;
&#xD;
        -  The need to decrease radiation-induced toxicity&#xD;
&#xD;
        -  The limit of CT-RT followed by durvalumab consolidation, leading to a high rate of&#xD;
           recurrence within the 18 months (18-month PFS rate of 44.2%)&#xD;
&#xD;
        -  The strong rationale to combine RT and PD-1 inhibition&#xD;
&#xD;
      It is hypothesized this innovative concept to be safe in the context of this study for the&#xD;
      following reasons:&#xD;
&#xD;
        -  The use of moderate accelerated intensity-modulated radiotherapy (H-IMRT) allows&#xD;
           decreasing both the Overall Treatment Time (OTT) and the dose to the organs at risk&#xD;
&#xD;
        -  The decrease of the OTT (24 fractions instead of 33 fractions) combined with a decrease&#xD;
           of the toxicity should represent a potential clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy (disease control rate) of accelerated IMRT combined with nivolumab as a first treatment line for patients with a locally advanced non-small cell lung cancer unfit for concomitant or sequential chemoradiotherapy and surgery.</measure>
    <time_frame>Control of the disease one year after treatment start</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Nivolumab and accelerated IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Nivolumab and Intensity Modulated Radiotherapy (IMRT)</intervention_name>
    <description>Every included patient will receive the experimental treatment regimen as follows:&#xD;
Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks&#xD;
Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption.</description>
    <arm_group_label>Nivolumab and accelerated IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage III non-small lung cancer;&#xD;
&#xD;
          -  Non-eligible to chemoradiotherapy, defined by multidisciplinary tumor board;&#xD;
&#xD;
          -  Eligible to radiotherapy, defined by multidisciplinary tumor board;&#xD;
&#xD;
          -  Performance Status Eastern Cooperative Oncology Group (ECOG) 0-2;&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Metastasis (M)0 based on clinical, Magnetic Resonance Imaging (MRI) of brain and&#xD;
             FluoroDeoxyGlucose (FDG)/ Positron Emission Tomography (PET)- computerized tomography&#xD;
             (CT) examinations;&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients eligible to surgery&#xD;
&#xD;
          -  Any prior or current treatment for invasive lung cancer&#xD;
&#xD;
          -  History of other malignancy within the last 3 years (exception of in situ carcinoma,&#xD;
             skin carcinomas, localized prostate carcinoma Gleason 6 and in situ breast carcinoma)&#xD;
&#xD;
          -  Significant disease which, in the judgment of the investigator, as a result of the&#xD;
             medical interview, physical examinations, or screening investigations would make the&#xD;
             patient inappropriate for entry into the trial&#xD;
&#xD;
          -  Known hypersensitivity reaction to nivolumab&#xD;
&#xD;
          -  Prior organ transplantation including allogenic stem-cell transplantation&#xD;
&#xD;
          -  Any social, personal, medical and/or psychologic factor(s) that could interfere with&#xD;
             the observance of the patient to the protocol and/or the follow-up and/or the&#xD;
             signature of the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joël Castelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine Gestin</last_name>
    <phone>+33(0)2 99 25 30 36</phone>
    <email>m.gestin@rennes.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Lucia, MD</last_name>
      <email>francois.lucia@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>François Lucia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Lerouge, MD</last_name>
      <email>d.lerouge@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine Lerouge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte contre le Cancer Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence Le Tinier, MD</last_name>
      <email>f-Letinier@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Le Tinier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte Contre le Cancer Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Gestin</last_name>
      <email>m.gestin@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Joël Castelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Hiret, MD</last_name>
      <email>sandrine.hiret@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine Hiret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Accelerated Intensity Modulated Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

